These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 11713396

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Urinary dosage of nuclear matrix protein 22 (NMP22) like biologic marker of transitional cell carcinoma (TCC): a study on patients with hematuria.
    Paoluzzi M, Cuttano MG, Mugnaini P, Salsano F, Giannotti P.
    Arch Ital Urol Androl; 1999 Feb; 71(1):13-8. PubMed ID: 10193018
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.
    Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS.
    J Urol; 1998 Feb; 159(2):394-8. PubMed ID: 9649246
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A.
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [Abstract] [Full Text] [Related]

  • 8. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
    Shariat SF, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP.
    J Urol; 2003 Dec; 170(6 Pt 1):2244-7. PubMed ID: 14634389
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
    Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M.
    J Urol; 1998 Jun; 159(6):1876-80. PubMed ID: 9598479
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
    Giannopoulos A, Manousakas T, Mitropoulos D, Botsoli-Stergiou E, Constantinides C, Giannopoulou M, Choremi-Papadopoulou H.
    Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation.
    Terrell JD, Elias KJ, Sagalowsky AI, Lotan Y.
    Int Braz J Urol; 2011 Jun; 37(6):706-11. PubMed ID: 22234001
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
    Del Nero A, Esposito N, Currò A, Biasoni D, Montanari E, Mangiarotti B, Trinchieri A, Zanetti G, Serrago MP, Pisani E.
    Eur Urol; 1999 Feb; 35(2):93-7. PubMed ID: 9933801
    [Abstract] [Full Text] [Related]

  • 20. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A, Kumar R, Gupta NP.
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.